Covid-19 Vaccine Market

A COVID-19 vaccine is a hypothetical vaccine against coronavirus disease 2019 (COVID-19). Although no vaccine has completed clinical trials, there are multiple attempts in progress to develop such a vaccine.

The genetic sequence of SARS-CoV-2, the coronavirus that causes COVID-19, was published on 11 January 2020, triggering intense global R&D activity to develop a vaccine against the disease. The scale of the humanitarian and economic impact of the COVID-19 pandemic is driving evaluation of next-generation vaccine technology platforms through novel paradigms to accelerate development, and the first COVID-19 vaccine candidate entered human clinical testing with unprecedented rapidity on 16 March 2020.

The global vaccine R&D effort in response to the COVID-19 pandemic is unprecedented in terms of scale and speed. Given the imperative for speed, there is an indication that vaccine could be available under emergency use or similar protocols by early 2021. This would represent a fundamental step change from the traditional vaccine development pathway, which takes on average over 10 years, even compared with the accelerated 5-year timescale for development of the first Ebola vaccine, and will necessitate novel vaccine development paradigms involving parallel and adaptive development phases, innovative regulatory processes and scaling manufacturing capacity.

Covid-19 Vaccine Market contains market size and forecasts of Covid-19 Vaccine in Global, including the following market information:

Global Covid-19 Vaccine Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Covid-19 Vaccine market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

DNA Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Covid-19 Vaccine include Moderna, CanSino Biologicals, Inovio Pharmaceuticals, Shenzhen Geno-Immune Medical Institute, GlaxoSmithKine, Pfizer, Johnson?Johnson, Heat Biologics and Sanofi. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Covid-19 Vaccine companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Covid-19 Vaccine Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Covid-19 Vaccine Market Segment Percentages, by Type, 2021 (%)

DNA

Non-replicating Viral Vector

Protein Subunit

RNA

Others

Global Covid-19 Vaccine Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Covid-19 Vaccine Market Segment Percentages, by Application, 2021 (%)

Adults

Children

Global Covid-19 Vaccine Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Covid-19 Vaccine Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Covid-19 Vaccine revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Covid-19 Vaccine revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Moderna

CanSino Biologicals

Inovio Pharmaceuticals

Shenzhen Geno-Immune Medical Institute

GlaxoSmithKine

Pfizer

Johnson?Johnson

Heat Biologics

Sanofi